Anti-fibrotic drugs dealing with pulmonary fibrosis after COVID-19-associated acute respiratory distress syndrome

• 作者: Abhijit S.Nair Sai Kaushik Pulipaka Praveen Kumar Kodisharapu Asiel Christopher
• 来源期刊: 急性病杂志（英文版）
• 年，卷（期）: 2021,（4）
• 所属期刊栏目: Letter to Editor
• 页码范围: 177-178
• 页数: 2页
• 语种: 英文
• DOI: 10.4103/2221-6189.318642

摘要

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus which is responsible for coronavirus disease (COVID-19), uses an angiotensin-2-converting enzyme (ACE2) as a cell receptor in humans. Initially, there is interstitial lung damage after infection, and then parenchymal lesions appear, which if not managed appropriately could worsen.